Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Sep 2023
Historique:
received: 13 08 2023
revised: 16 09 2023
accepted: 28 09 2023
medline: 1 11 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

The human T-cell leukemia virus type 1 (HTLV-1) is the only known human oncogenic retrovirus. HTLV-1 can cause a type of cancer called adult T-cell leukemia/lymphoma (ATL). The virus is transmitted through the body fluids of infected individuals, primarily breast milk, blood, and semen. At least 5-10 million people in the world are infected with HTLV-1. In addition to ATL, HTLV-1 infection can also cause HTLV-I-associated myelopathy (HAM/TSP). ATL is characterized by a low viral expression and poor prognosis. The oncogenic mechanism triggered by HTLV-1 is extremely complex and the molecular pathways are not fully understood. However, viral regulatory proteins Tax and HTLV-1 bZIP factor (HBZ) have been shown to play key roles in the transformation of HTLV-1-infected T cells. Moreover, several studies have shown that the final fate of HTLV-1-infected transformed Tcell clones is the result of a complex interplay of HTLV-1 oncogenic protein expression with cellular transcription factors that subvert the cell cycle and disrupt regulated cell death, thereby exerting their transforming effects. This review provides updated information on the mechanisms underlying the transforming action of HTLV-1 and highlights potential therapeutic targets to combat ATL.

Identifiants

pubmed: 37834255
pii: ijms241914807
doi: 10.3390/ijms241914807
pmc: PMC10572738
pii:
doi:

Substances chimiques

Retroviridae Proteins 0
Basic-Leucine Zipper Transcription Factors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Biomark Res. 2018 Jul 18;6:24
pubmed: 30034808
J Biol Chem. 2012 Jun 15;287(25):21357-70
pubmed: 22553204
Oncogene. 1997 May 15;14(19):2265-72
pubmed: 9178902
PLoS Pathog. 2022 May 16;18(5):e1010387
pubmed: 35576236
Blood. 2001 Aug 1;98(3):823-9
pubmed: 11468184
BMC Cancer. 2018 Aug 6;18(1):791
pubmed: 30081901
Mol Cell Biol. 1994 Oct;14(10):6443-51
pubmed: 7935369
Front Cell Infect Microbiol. 2020 Dec 23;10:580371
pubmed: 33425776
JCI Insight. 2019 May 23;5:
pubmed: 31120863
Front Immunol. 2022 Aug 16;13:978800
pubmed: 36052071
Mol Cell Biol. 1998 Feb;18(2):721-31
pubmed: 9447968
PLoS Comput Biol. 2020 Sep 17;16(9):e1007470
pubmed: 32941445
Cancer Med. 2022 Sep;11(17):3238-3250
pubmed: 35315593
Science. 1995 Jul 7;269(5220):79-81
pubmed: 7604283
AIDS Res Hum Retroviruses. 2002 Feb 10;18(3):207-12
pubmed: 11839155
Oncogene. 1995 Jan 19;10(2):269-77
pubmed: 7838527
Blood Adv. 2022 Apr 12;6(7):2346-2360
pubmed: 35030628
Cancer Cell. 2018 Aug 13;34(2):286-297.e10
pubmed: 30057145
J Clin Oncol. 2012 Mar 10;30(8):837-42
pubmed: 22312108
Blood. 2006 May 15;107(10):3976-82
pubmed: 16424388
Sci Rep. 2016 Mar 04;6:22555
pubmed: 26939770
Cancer Res. 2014 Jan 1;74(1):188-200
pubmed: 24177179
J Biol Chem. 2008 Aug 29;283(35):23903-13
pubmed: 18599479
PLoS Pathog. 2021 Feb 1;17(2):e1009271
pubmed: 33524072
Front Cell Infect Microbiol. 2019 Mar 22;9:69
pubmed: 30968001
Biochem Biophys Res Commun. 2015 Oct 2;465(4):739-45
pubmed: 26319552
PLoS Pathog. 2021 Jan 20;17(1):e1009219
pubmed: 33471856
Blood. 2010 Jul 8;116(1):54-62
pubmed: 20395415
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
J Virol. 2004 Jul;78(13):6735-43
pubmed: 15194748
J Gen Virol. 1997 Dec;78 ( Pt 12):3277-85
pubmed: 9400978
Viruses. 2016 Feb 03;8(2):
pubmed: 26848683
Front Immunol. 2023 Feb 03;14:1043600
pubmed: 36817417
J Biol Chem. 1998 May 29;273(22):13768-75
pubmed: 9593719
Haematologica. 2021 Aug 01;106(8):2076-2085
pubmed: 33626865
Nat Med. 2004 Feb;10(2):197-201
pubmed: 14730358
Retrovirology. 2015 Nov 09;12:91
pubmed: 26552867
Retrovirology. 2019 Dec 18;16(1):43
pubmed: 31852543
Oncogene. 1999 Nov 22;18(49):6948-58
pubmed: 10602469
J Virol. 2012 Sep;86(17):9070-8
pubmed: 22696638
Int J Hematol. 2023 Apr;117(4):504-511
pubmed: 36705848
Int J Oncol. 2017 Aug;51(2):633-643
pubmed: 28586006
Cell Death Discov. 2020 Feb 18;6:9
pubmed: 32123585
Br J Cancer. 2009 Nov 3;101(9):1497-501
pubmed: 19861996
Trends Genet. 2021 Jul;37(7):639-656
pubmed: 33896583
Cancer Res. 2015 Oct 1;75(19):4143-52
pubmed: 26383166
Retrovirology. 2016 Jan 08;13:3
pubmed: 26745892
FEMS Microbiol Rev. 2022 Nov 2;46(6):
pubmed: 35810003
J Virol. 2018 Jul 17;92(15):
pubmed: 29769340
Proc Natl Acad Sci U S A. 1986 Nov;83(21):8112-6
pubmed: 3022280
AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68
pubmed: 7531462
J Exp Clin Cancer Res. 2016 Jul 22;35(1):118
pubmed: 27448598
Oncogene. 2002 Oct 17;21(47):7241-6
pubmed: 12370815
Blood Adv. 2017 May 5;1(12):748-752
pubmed: 29296718
Int J Mol Sci. 2022 May 14;23(10):
pubmed: 35628297
Pharmacology. 2023;108(3):224-237
pubmed: 36889301
J Biol Chem. 2001 Nov 2;276(44):40385-8
pubmed: 11553609
NeuroImmune Pharm Ther. 2023 Mar 25;2(1):49-62
pubmed: 37027342
Blood Adv. 2019 Feb 26;3(4):564-569
pubmed: 30787019
Int J Cancer. 2005 Jul 20;115(6):967-74
pubmed: 15729715
Cancer Sci. 2017 Sep;108(9):1719-1725
pubmed: 28627735
Cancer Sci. 2022 Aug;113(8):2778-2787
pubmed: 35579212
J Virol. 1995 Mar;69(3):1834-41
pubmed: 7853524
J Clin Oncol. 2019 Mar 10;37(8):677-687
pubmed: 30657736
Biochem Biophys Res Commun. 2023 May 21;657:43-49
pubmed: 36972660
J Virol. 2002 Dec;76(24):12813-22
pubmed: 12438606
Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41
pubmed: 26990581
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1269-E1278
pubmed: 29358408
Mol Cell Biol. 1998 Sep;18(9):5157-65
pubmed: 9710600
Virology. 1997 Apr 28;231(1):135-40
pubmed: 9143312
Blood Cancer J. 2023 May 3;13(1):67
pubmed: 37137914
Gene. 2007 Jan 15;386(1-2):191-201
pubmed: 17071021
Cancer Res. 2014 Nov 1;74(21):6082-93
pubmed: 25205102
Pathogens. 2020 Jul 07;9(7):
pubmed: 32645846
Blood Adv. 2020 Nov 10;4(21):5574-5579
pubmed: 33170933
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15213-8
pubmed: 16217039
J Virol. 2021 Nov 9;95(23):e0135821
pubmed: 34549986
Viruses. 2016 Mar 14;8(3):80
pubmed: 26985903
Mol Cell Biol. 2000 Nov;20(22):8580-9
pubmed: 11046153
Cell Cycle. 2011 Oct 1;10(19):3337-45
pubmed: 21957492
Cells. 2021 Apr 01;10(4):
pubmed: 33916140
Hematol Oncol. 2023 Aug;41(3):389-395
pubmed: 36513602
Curr Opin Virol. 2012 Aug;2(4):474-81
pubmed: 22819021
Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20738-43
pubmed: 21076035
Blood. 2023 Mar 9;141(10):1159-1168
pubmed: 36150143
Front Microbiol. 2020 May 28;11:1062
pubmed: 32547515
PLoS One. 2021 Aug 18;16(8):e0256320
pubmed: 34407152
Anticancer Res. 2023 May;43(5):1901-1908
pubmed: 37097671
PLoS Pathog. 2022 Nov 28;18(11):e1010774
pubmed: 36441826
Front Microbiol. 2020 May 19;11:979
pubmed: 32508789
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5
pubmed: 26396258
Proc Natl Acad Sci U S A. 1985 Apr;82(8):2277-81
pubmed: 2986109
Cell Chem Biol. 2017 Nov 16;24(11):1377-1387.e3
pubmed: 28965728
Retrovirology. 2021 Feb 23;18(1):6
pubmed: 33622348
J Virol. 2016 Jan 20;90(7):3600-10
pubmed: 26792732
Nat Med. 2010 Jan;16(1):83-9
pubmed: 20023636
J Virol. 2004 Oct;78(20):11077-83
pubmed: 15452228
Science. 2001 May 11;292(5519):1106-9
pubmed: 11352065
PLoS Pathog. 2011 Apr;7(4):e1002025
pubmed: 21552325
Viruses. 2011 Jun;3(6):750-69
pubmed: 21994752
Blood. 2012 Jul 19;120(3):572-80
pubmed: 22589473
Virus Genes. 2001 Jun;22(3):279-87
pubmed: 11450946
Intern Med. 2023 Feb 15;62(4):613-616
pubmed: 35871596
FEBS Lett. 2010 May 17;584(10):2070-5
pubmed: 20170654
J Med Virol. 2004 Nov;74(3):473-83
pubmed: 15368513
Leukemia. 2013 Aug;27(8):1621-7
pubmed: 23411465
Viruses. 2022 Sep 14;14(9):
pubmed: 36146843
Int J Hematol. 2023 Apr;117(4):512-522
pubmed: 36862273
Virology. 2010 Aug 1;403(2):173-80
pubmed: 20471052
Mol Ther. 2023 Jul 5;31(7):2266-2285
pubmed: 36934299
J Biol Chem. 1989 Sep 15;264(26):15236-41
pubmed: 2768259
Eur J Haematol. 2020 Dec;105(6):763-772
pubmed: 32780889

Auteurs

Francesca Marino-Merlo (F)

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.

Sandro Grelli (S)

Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.

Antonio Mastino (A)

The Institute of Translational Pharmacology, CNR, 00133 Rome, Italy.

Michele Lai (M)

Retrovirus Center and Virology Section, Department of Translational Research, University of Pisa, 56100 Pisa, Italy.

Paola Ferrari (P)

Unit of Oncology, Department of Medical and Oncological Area, Azienda Ospedaliera-Universitaria Pisana, 56125 Pisa, Italy.

Andrea Nicolini (A)

Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, 56126 Pisa, Italy.

Mauro Pistello (M)

Retrovirus Center and Virology Section, Department of Translational Research, University of Pisa, 56100 Pisa, Italy.

Beatrice Macchi (B)

Department of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH